PRTK's omadacycline might not perform as well in urinary tract infections as it does in pneumonia or skin infections.
PRTK has secured some funding from BARDA, highlighting the potential of omadacycline in treating or even preventing anthrax infection.
The DISARM Act could serve as a potential boon for PRTK and other antibiotics makers, but when that might happen is uncertain.
Antibiotics maker, Paratek Pharmaceuticals (PRTK), has struggled to hold onto gains in 2019. The has been a recent setback in the clinic but success on the funding front, both of which are worth